Michaelia Cash (WA, Liberal Party, Minister for Employment, Skills, Small and Family Business) Share this | Hansard source

The government's two new production and supply agreements have secured an additional 50 million doses, securing early access to 134 million doses of a COVID-19 vaccine for Australians in 2020-21 and 2021-22. Australians will have access to 33.8 million doses of the Oxford vaccine, 51 million doses of the UQ vaccine, 40 million doses of the Novavax protein subunit vaccine and 10 million doses of the promising FISABIO vaccine. All four vaccine candidates are likely to require two doses per person. CSL has confirmed its Australian manufacturing schedule is on track to produce 30 million doses of the Oxford-AstraZeneca COVID-19 vaccine candidate. Subject to regulatory approvals, first doses will be ready for use in early 2021.